127% Return in 1 Year: This Multibagger Pharma Company Approves Rs 100 Crore Change in IPO Fund Utilisation; Check Details
Join Us
Follow Us
Senores Pharmaceuticals has approved a proposal to reallocate Rs 100.02 crore of its unutilised IPO proceeds, subject to shareholder approval through a postal ballot
✨ Key Takeaways
On Tuesday, Indian equity markets traded marginally higher, supported by positive global cues despite renewed geopolitical tensions. The Nifty 50 rose 3.90 points, or 0.02 per cent, to 23,950.15, while the Sensex gained 66.71 points, or 0.09 per cent, to 76,795.08. In the broader market, the Nifty MidCap and Nifty SmallCap indices advanced 0.23 per cent and 0.48 per cent, respectively. Amid the positive market sentiment, Senores Pharmaceuticals share price was trading at Rs 1,322.30, up 0.20 per cent.
Senores Pharmaceuticals Approves Change in IPO Fund Utilisation
Senores Pharmaceuticals Limited informed the stock exchanges that its Board of Directors, based on the recommendation of the Audit Committee, has approved a proposal to vary the utilisation of the unutilised portion of its Initial Public Offering (IPO) proceeds. The proposal involves the reallocation of Rs 100.02 crore out of the company's total primary IPO proceeds of Rs 500 crore. The proposal will now be placed before shareholders for approval through a postal ballot.
The company stated that the decision was approved during the Board meeting held on June 29, 2026, which commenced at 4:15 PM and concluded at 5:00 PM. The revised utilisation plan will become effective only after receiving shareholder approval.
Also Read - This New Mutual-- Fund Aims to Balance Equity, Debt and Precious Metals; Check Details
Why Senores Pharmaceuticals Revise IPO Fund Utilisation
Companies may revise the utilisation of IPO proceeds to better align capital allocation with evolving business priorities, expansion opportunities or operational requirements. Such changes require shareholder approval to ensure transparency and appropriate governance in the use of funds raised from public investors.
About Senores Pharmaceuticals
Senores Pharmaceuticals Limited is a pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical formulations across regulated and emerging markets. The company focuses on delivering high-quality healthcare products while expanding its presence through product development, strategic partnerships and international market expansion.
Add DSIJ as your preferred news source on G o o g l e
Add NowWhat are your thoughts on Senores Pharmaceuticals' proposed change in IPO fund utilisation? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.